Compare Macy's Inc (M) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs ResMed Inc. — how do they compare? Macy's Inc trades at $23.61 (market cap $6.13B), while ResMed Inc. trades at $195.48 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 4.7× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.29%). Which is the better fit depends on your goals.
| M | RMD | |
|---|---|---|
Market Cap | $6.13B | $28.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.96 | $293.73 |
52-Week Low | $11.90 | $182.82 |
Enterprise Value | $9.95B | $27.99B |
Dividend Yield | 3.29% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $23.39, down 1.22% on the day, with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. Positive sentiment is driven by the 'Bold New Chapter' turnaround strategy, with Berkshire Hathaway's new 3.04 million-share position adding institutional confidence.
The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 6% upside potential. Key opportunities include luxury brand expansion and digital transformation, while risks involve margin pressure from store closures and macroeconomic sensitivity. The stock presents value characteristics with growth catalysts from operational improvements.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
